GLG Partners LP acquired a new position in shares of Merus Labs International Inc (NASDAQ:MSLI) (TSE:MSL) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,300,000 shares of the company’s stock, valued at approximately $4,167,000.

Several other hedge funds have also recently added to or reduced their stakes in MSLI. Goldman Sachs Group Inc. grew its holdings in shares of Merus Labs International by 3,995.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,093,541 shares of the company’s stock worth $1,378,000 after purchasing an additional 1,066,837 shares during the period. Glazer Capital LLC acquired a new stake in Merus Labs International during the 2nd quarter worth approximately $496,000. Vanguard Group Inc. acquired a new stake in Merus Labs International during the 2nd quarter worth approximately $756,000. OMERS ADMINISTRATION Corp acquired a new stake in Merus Labs International during the 2nd quarter worth approximately $1,358,000. Finally, Kassirer Asset Management Corp acquired a new stake in Merus Labs International during the 2nd quarter worth approximately $2,054,000. Institutional investors and hedge funds own 19.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/glg-partners-lp-invests-4-17-million-in-merus-labs-international-inc-msli/1603371.html.

Merus Labs International Inc (NASDAQ MSLI) remained flat at $1.30 during mid-day trading on Monday. The company had a trading volume of 9,409 shares. Merus Labs International Inc has a one year low of $0.70 and a one year high of $1.33. The company’s 50 day moving average is $1.20 and its 200-day moving average is $0.94.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Want to see what other hedge funds are holding MSLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merus Labs International Inc (NASDAQ:MSLI) (TSE:MSL).

Institutional Ownership by Quarter for Merus Labs International (NASDAQ:MSLI)

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.